Zentek Ltd. (NASDAQ:ZTEK - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 80,000 shares, a growth of 36.3% from the March 15th total of 58,700 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 42,000 shares, the short-interest ratio is presently 1.9 days.Institutional Inflows and OutflowsInstitutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new position in shares of Zentek during the fourth quarter valued at approximately $31,000. Scotia Capital Inc. lifted its stake in shares of Zentek by 5.7% during the 4th quarter. Scotia Capital Inc. now owns 958,771 shares of the company's stock worth $867,000 after purchasing an additional 51,744 shares during the period. Finally, Anson Funds Management LP acquired a new stake in shares of Zentek during the fourth quarter worth $145,000. Institutional investors and hedge funds own 0.77% of the company's stock. Zentek Price PerformanceZTEK traded down $0.04 on Friday, reaching $1.11. 13,933 shares of the company's stock were exchanged, compared to its average volume of 38,593. The stock's fifty day moving average price is $1.04 and its 200-day moving average price is $0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.83 and a quick ratio of 1.48. The stock has a market cap of $115.49 million, a PE ratio of -15.80 and a beta of 0.93. Zentek has a twelve month low of $0.50 and a twelve month high of $1.31. Zentek (NASDAQ:ZTEK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.01) EPS for the quarter. Zentek had a negative net margin of 16,555.32% and a negative return on equity of 58.13%. About Zentek (Get Free Report)Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.See AlsoFive stocks we like better than ZentekHow to Short a Stock in 5 Easy Steps 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks3 Ways To Invest In Coffee, Other Than Drinking ItThese 3 Stocks Have Huge Last 12 Months Shareholder YieldsRussell 2000 Index, How Investors Use it For Profitable TradingProminent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Zentek Right Now?Before you consider Zentek, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentek wasn't on the list.While Zentek currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here